The Ratio of Peripheral Regulatory T Cells to Lox-1 Polymorphonuclear Myeloid-derived Suppressor Cells Predicts the Early Response to Anti-PD-1 Therapy in Patients with Non-Small Cell Lung Cancer.
作者信息
Kim Hye Ryun, Park Su-Myeong, Seo Sang-Uk, Jung Inkyung, Yoon Hong In, Gabrilovich Dmitry I, Cho Byoung Chul, Seong Seung-Yong, Ha Sang-Jun, Youn Je-In
机构信息
1 Yonsei University College of Medicine Seoul, Korea.
2 Seoul National University College of Medicine Seoul, Korea.
出版信息
Am J Respir Crit Care Med. 2019 Jan 15;199(2):243-246. doi: 10.1164/rccm.201808-1502LE.
Abstract
摘要
相似文献
1
The Ratio of Peripheral Regulatory T Cells to Lox-1 Polymorphonuclear Myeloid-derived Suppressor Cells Predicts the Early Response to Anti-PD-1 Therapy in Patients with Non-Small Cell Lung Cancer.外周调节性T细胞与凝集素样氧化低密度脂蛋白受体1（Lox-1）多形核髓源性抑制细胞的比例可预测非小细胞肺癌患者对抗程序性死亡蛋白1（PD-1）治疗的早期反应。
Am J Respir Crit Care Med. 2019 Jan 15;199(2):243-246. doi: 10.1164/rccm.201808-1502LE.
2
Peripheral natural killer cells and myeloid-derived suppressor cells correlate with anti-PD-1 responses in non-small cell lung cancer.外周自然杀伤细胞和髓系来源的抑制细胞与非小细胞肺癌的抗 PD-1 反应相关。
Sci Rep. 2020 Jun 3;10(1):9050. doi: 10.1038/s41598-020-65666-x.
3
Entinostat Neutralizes Myeloid-Derived Suppressor Cells and Enhances the Antitumor Effect of PD-1 Inhibition in Murine Models of Lung and Renal Cell Carcinoma.恩替诺特中和髓源性抑制细胞，并增强 PD-1 抑制在肺和肾细胞癌小鼠模型中的抗肿瘤作用。
Clin Cancer Res. 2017 Sep 1;23(17):5187-5201. doi: 10.1158/1078-0432.CCR-17-0741. Epub 2017 Jul 11.
4
Safety of an anti-PD-1 immune checkpoint inhibitor in a liver transplant recipient.抗PD-1免疫检查点抑制剂在肝移植受者中的安全性。
Ann Oncol. 2018 Jan 1;29(1):286-287. doi: 10.1093/annonc/mdx548.
5
MDSC subtypes and CD39 expression on CD8 T cells predict the efficacy of anti-PD-1 immunotherapy in patients with advanced NSCLC.骨髓来源抑制细胞亚群和 CD8 T 细胞上的 CD39 表达可预测晚期 NSCLC 患者抗 PD-1 免疫治疗的疗效。
Eur J Immunol. 2020 Nov;50(11):1810-1819. doi: 10.1002/eji.202048534. Epub 2020 Jul 9.
6
Anti-PD-1-related cryoglobulinemia during treatment with nivolumab in NSCLC patient.非小细胞肺癌患者接受纳武单抗治疗期间出现的与抗程序性死亡蛋白1相关的冷球蛋白血症。
Ann Oncol. 2017 Jun 1;28(6):1405-1406. doi: 10.1093/annonc/mdx126.
7
KEYNOTE-024: Unlocking a pathway to lung cancer cure?KEYNOTE-024：开启肺癌治愈之路？
J Thorac Cardiovasc Surg. 2018 Apr;155(4):1777-1780. doi: 10.1016/j.jtcvs.2017.10.155. Epub 2017 Dec 23.
8
The Combination of MEK Inhibitor With Immunomodulatory Antibodies Targeting Programmed Death 1 and Programmed Death Ligand 1 Results in Prolonged Survival in Kras/p53-Driven Lung Cancer.MEK 抑制剂联合靶向程序性死亡受体 1 和程序性死亡配体 1 的免疫调节抗体可延长 Kras/p53 驱动的肺癌患者的生存时间。
J Thorac Oncol. 2019 Jun;14(6):1046-1060. doi: 10.1016/j.jtho.2019.02.004. Epub 2019 Feb 13.
9
[Immuno-checkpoint inhibitor resistance and strategy in lung cancer].[肺癌中的免疫检查点抑制剂耐药性及策略]
Zhonghua Jie He He Hu Xi Za Zhi. 2020 Jul 12;43(7):603-606. doi: 10.3760/cma.j.cn112147-20200312-00319.
10
A Combined PD-1/C5a Blockade Synergistically Protects against Lung Cancer Growth and Metastasis.联合 PD-1/C5a 阻断协同保护对抗肺癌生长和转移。
Cancer Discov. 2017 Jul;7(7):694-703. doi: 10.1158/2159-8290.CD-16-1184. Epub 2017 Mar 13.
引用本文的文献
1
Pre-treatment monocytic myeloid-derived suppressor cells as predictive biomarkers for immune checkpoint inhibitor response in clear cell renal cell carcinoma.治疗前单核细胞来源的髓系抑制细胞作为透明细胞肾细胞癌免疫检查点抑制剂反应的预测生物标志物。
Front Immunol. 2025 Aug 21;16:1641383. doi: 10.3389/fimmu.2025.1641383. eCollection 2025.
2
Beyond the tumor microenvironment: Orchestrating systemic T‑cell response for next‑generation cancer immunotherapy (Review).超越肿瘤微环境：为下一代癌症免疫疗法协调全身T细胞反应（综述）
Int J Oncol. 2025 Jul;67(1). doi: 10.3892/ijo.2025.5762. Epub 2025 Jun 13.
3
Myeloid-Derived Suppressor Cells in Cancer: Mechanistic Insights and Targeted Therapeutic Innovations.癌症中的髓源性抑制细胞：机制洞察与靶向治疗创新
MedComm (2020). 2025 May 31;6(6):e70231. doi: 10.1002/mco2.70231. eCollection 2025 Jun.
4
Targeting neutrophils for cancer therapy.以中性粒细胞为靶点进行癌症治疗。
Nat Rev Drug Discov. 2025 May 15. doi: 10.1038/s41573-025-01210-8.
5
Harnessing myeloid cells in cancer.利用癌症中的髓样细胞。
Mol Cancer. 2025 Mar 6;24(1):69. doi: 10.1186/s12943-025-02249-2.
6
Early changes of peripheral circulating immune subsets induced by PD-1 inhibitors in patients with advanced malignant melanoma and non-small cell lung cancer.程序性死亡受体1（PD-1）抑制剂对晚期恶性黑色素瘤和非小细胞肺癌患者外周循环免疫亚群的早期影响
BMC Cancer. 2024 Dec 30;24(1):1590. doi: 10.1186/s12885-024-13351-x.
7
Predictive biomarkers for immune checkpoint inhibitors therapy in lung cancer.预测免疫检查点抑制剂治疗肺癌的生物标志物。
Hum Vaccin Immunother. 2024 Dec 31;20(1):2406063. doi: 10.1080/21645515.2024.2406063. Epub 2024 Oct 16.
8
Immune checkpoint blockade resistance in lung cancer: emerging mechanisms and therapeutic opportunities.肺癌免疫检查点阻断耐药：新出现的机制和治疗机会。
Trends Pharmacol Sci. 2024 Jun;45(6):520-536. doi: 10.1016/j.tips.2024.04.006. Epub 2024 May 13.
9
CD137 and regulatory T cells as independent prognostic factors of survival in advanced non-oncogene addicted NSCLC patients treated with immunotherapy as first-line.CD137 和调节性 T 细胞作为一线免疫治疗治疗的晚期非成瘾性非小细胞肺癌患者生存的独立预后因素。
J Transl Med. 2024 Apr 3;22(1):329. doi: 10.1186/s12967-024-05142-6.
10
Molecular assessment of intratumoral immune cell subsets and potential mechanisms of resistance to odronextamab, a CD20×CD3 bispecific antibody, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.肿瘤内免疫细胞亚群的分子评估及奥妥珠单抗（一种 CD20×CD3 双特异性抗体）治疗复发/难治性 B 细胞非霍奇金淋巴瘤患者耐药的潜在机制。
J Immunother Cancer. 2024 Mar 21;12(3):e008338. doi: 10.1136/jitc-2023-008338.
本文引用的文献
1
Understanding the tumor immune microenvironment (TIME) for effective therapy.理解肿瘤免疫微环境（TIME）以实现有效的治疗。
Nat Med. 2018 May;24(5):541-550. doi: 10.1038/s41591-018-0014-x. Epub 2018 Apr 23.
2
Circulating and Tumor Myeloid-derived Suppressor Cells in Resectable Non-Small Cell Lung Cancer.可切除非小细胞肺癌中的循环和肿瘤髓系来源的抑制细胞。
Am J Respir Crit Care Med. 2018 Sep 15;198(6):777-787. doi: 10.1164/rccm.201708-1707OC.
3
Cancer immunotherapy using checkpoint blockade.使用免疫检查点阻断的癌症免疫疗法。
Science. 2018 Mar 23;359(6382):1350-1355. doi: 10.1126/science.aar4060. Epub 2018 Mar 22.
4
High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy.高维单细胞分析预测抗 PD-1 免疫治疗反应。
Nat Med. 2018 Feb;24(2):144-153. doi: 10.1038/nm.4466. Epub 2018 Jan 8.
5
HMGB1 promotes myeloid-derived suppressor cells and renal cell carcinoma immune escape.高迁移率族蛋白B1促进髓源性抑制细胞及肾细胞癌免疫逃逸。
Oncotarget. 2017 Jun 28;8(38):63290-63298. doi: 10.18632/oncotarget.18796. eCollection 2017 Sep 8.
6
Lectin-type oxidized LDL receptor-1 distinguishes population of human polymorphonuclear myeloid-derived suppressor cells in cancer patients.凝集素型氧化型低密度脂蛋白受体-1可区分癌症患者中人类多形核髓源性抑制细胞群体。
Sci Immunol. 2016 Aug;1(2). doi: 10.1126/sciimmunol.aaf8943. Epub 2016 Aug 5.
7
CXCL2/MIF-CXCR2 signaling promotes the recruitment of myeloid-derived suppressor cells and is correlated with prognosis in bladder cancer.CXCL2/MIF-CXCR2 信号通路促进髓源性抑制细胞的募集，并与膀胱癌的预后相关。
Oncogene. 2017 Apr;36(15):2095-2104. doi: 10.1038/onc.2016.367. Epub 2016 Oct 10.
8
Expansion of myeloid derived suppressor cells correlates with number of T regulatory cells and disease progression in myelodysplastic syndrome.髓系来源的抑制性细胞扩增与骨髓增生异常综合征中调节性T细胞数量及疾病进展相关。
Oncoimmunology. 2015 Jun 24;5(2):e1062208. doi: 10.1080/2162402X.2015.1062208. eCollection 2016 Feb.
9
CCL9 Induced by TGFβ Signaling in Myeloid Cells Enhances Tumor Cell Survival in the Premetastatic Organ.骨髓细胞中由转化生长因子β信号诱导产生的CCL9增强了肿瘤细胞在转移前器官中的存活能力。
Cancer Res. 2015 Dec 15;75(24):5283-98. doi: 10.1158/0008-5472.CAN-15-2282-T. Epub 2015 Oct 19.
10
Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer.抗原识别改变是癌症中CD8 + T细胞耐受的一种机制。
Nat Med. 2007 Jul;13(7):828-35. doi: 10.1038/nm1609. Epub 2007 Jul 1.
Zotero 插件